



**Vaccines and Global Health: The Week in Review  
8 August 2020 :: Number 563  
Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday evening at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. This blog allows full-text searching of over 9,000 entries.*

*Comments and suggestions should be directed to  
David R. Curry, MS  
Editor and  
Executive Director  
Center for Vaccine Ethics & Policy  
[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

**Request email delivery of the pdf:** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

**Support this knowledge-sharing service:** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

**Contents** *[click on link below to move to associated content]*

- A. [Milestones :: Perspectives :: Featured Journal Content](#)
- B. [Emergencies](#)
- C. [WHO; CDC \[U.S., Africa, China\]](#)
- D. [Announcements](#)
- E. [Journal Watch](#)
- F. [Media Watch](#)



## ***Milestones :: Perspectives :: Research***

.....  
.....

### **EMERGENCIES**

#### **Coronavirus [COVID-19]**

*Public Health Emergency of International Concern (PHEIC)*

#### **Situation report - 201**

Coronavirus disease 2019 (COVID-19)

8 August 2020

Confirmed cases :: 19 187 943 [week ago: 17 396 943]

Confirmed deaths :: 716 075 [week ago: 635 173]

#### ***Highlights [selected]***

:: WHO has published guidance on the public health surveillance of coronavirus disease 2019 (COVID-19) in humans caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This document combines and supersedes the Global surveillance guidance for COVID-19 caused by human infection with COVID-19 virus: Interim guidance, and Surveillance strategies for COVID-19 human infection: Interim Guidance 10 May 2020.

:: A plane carrying 20 tonnes of trauma and surgical supplies from WHO has landed in Beirut, Lebanon to support the treatment of patients injured by the blast which occurred in the city on 4 August. This latest emergency has occurred at a time of recent civil unrest, economic crisis, the COVID-19 outbreak and heavy refugee burden. "We are in this together, and we are committed to supporting Lebanon in this very difficult time" said Dr Najat Rochdi, UN Resident Coordinator in Lebanon...

.....  
.....

### **COVID-19 Vaccines – Access/Procurement/Supply**

#### **Up to 100 million COVID-19 vaccine doses to be made available for low- and middle-income countries as early as 2021**

***:: New landmark collaboration between the Serum Institute of India (SII), Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation to accelerate manufacturing and delivery of up to 100 million doses of future safe and effective COVID-19 vaccines for low- and middle-income countries in 2021***

*:: Vaccines will be priced at maximum US\$ 3 per dose and made available to up to 92 countries included in Gavi's COVAX Advance Market Commitment (AMC)*

*:: Dr Seth Berkley: New collaboration will help "ensure we have additional manufacturing capacity to begin producing doses for every country, not just the wealthy few"*

Geneva, 7 August 2020 – A new landmark collaboration between SII, the world's largest vaccine manufacturer by volume, Gavi and the Bill & Melinda Gates Foundation will accelerate the manufacture and delivery of up to 100 million doses of COVID-19 vaccines for low- and middle-income countries (LMICs) as part of the Gavi COVAX AMC, a mechanism within the COVAX Facility.

**The collaboration will provide upfront capital to SII to help them increase manufacturing capacity now so that, once a vaccine, or vaccines, gains regulatory approval and WHO Prequalification, doses can be produced at scale for distribution to LMIC countries as part of the Gavi COVAX AMC mechanism as early as the first half of 2021.**

"Too many times we've seen the most vulnerable countries left at the back of the queue when it comes to new treatments, new diagnostics and new vaccines," said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance. "With COVID-19 vaccines we want things to be different. If only the wealthiest countries in the world are protected, then international trade, commerce and society as a whole will continue to be hit hard as the pandemic continues to rage across the globe. This new collaboration is an important step in our efforts to prevent this from happening, helping to ensure we have additional manufacturing capacity to begin producing doses for every country, not just the wealthy few. We now need other vaccine manufacturers to step up and follow SII's lead."

**The funding will help de-risk manufacturing by SII for candidate vaccines from AstraZeneca and Novavax, which will be available for procurement if they are successful in attaining full licensure and WHO Prequalification.** SII has set a ceiling price of US\$ 3 per dose, a price enabled by investments made by partners such as CEPI and the Bill & Melinda Gates Foundation. The arrangement also provides an option to secure additional doses if the vaccines pillar of the ACT Accelerator sees a need for it.

"In an attempt to make our fight against COVID-19 stronger and all-embracing; SII has partnered with Gavi and the Bill & Melinda Gates Foundation to advance the manufacturing and delivery of up to 100 million doses of future COVID vaccines for low and middle income countries in 2021," said Adar Poonawalla, CEO of Serum Institute of India. "The rampant spread of the virus has rendered the entire world in an unimaginable halt of uncertainty. And to ensure maximum immunization coverage and contain the pandemic, it is important to make sure that the most remote and poorest countries of the world have access to affordable cure and preventive measures. Through this association, we seek to ramp up our constant efforts to save the lives of millions of people from this dreadful disease."

**The Gavi COVAX AMC, which is currently seeking at least US\$ 2 billion in initial seed funding, will meet at least part of the cost of procurement for the vaccine doses. Last week the Gavi Board agreed upon the final list of 92 countries that will be supported by the AMC. Under the new collaboration, AstraZeneca's candidate vaccine, if successful, will be available to 57 Gavi-eligible countries. Novavax's candidate, if successful, will be available to all 92 countries supported by the AMC. These countries align with SII's licensing agreements with the two partners.**

This collaboration underscores India's proven-track record in developing safe and quality vaccines. There is a long history of Gavi and pharmaceutical companies successfully partnering with Indian manufactures, particularly the Serum Institute of India, to manufacture vaccines that protect against meningitis, severe diarrhoea, pneumonia and measles.

"It is encouraging to see an Indian vaccine manufacturer, SII, work collaboratively with global partners with a view to making available affordable Covid-19 vaccine supplies for India and the world," said Professor K VijayRaghavan, Principal Scientific Adviser to the Government of India. "Normally it would take more than a decade to develop such a vaccine but with the efforts of our researchers, academia and private sector, working closely with global collaborators we are hopeful of accelerating the availability of a successful vaccine, at reasonable cost and in sufficient quantities, to fight the pandemic."

"Researchers are making good progress on developing safe and effective vaccines for COVID-19," said Bill Gates, co-chair of the Bill & Melinda Gates Foundation. "But making sure everyone has access to them, as soon as possible, will require tremendous manufacturing capacity and a global distribution network. This collaboration gives the world some of both: the power of India's manufacturing sector and Gavi's supply chain. It's just a start. Organizations like Gavi and CEPI need much more support to facilitate development and delivery of hundreds of millions - maybe billions - of vaccine doses by next year."

The collaboration between Gavi, SII, and the Gates Foundation supports the efforts of the ACT Accelerator's vaccines pillar, also known as COVAX, co-led by Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization (WHO), to accelerate the development of COVID-19 vaccines and ensure rapid, global access to them. Decisions around investment in manufacturing are taken in close collaboration between these three lead organisations of the COVAX pillar.

Under the COVAX umbrella, Gavi is leading the COVAX Facility, which provides governments with the opportunity to benefit from a large portfolio of COVID-19 candidate vaccines using a range of technology platforms, produced by more manufacturers across the world, with a bigger market to provide security of demand. The Facility, which is available to any country or economy, includes the AMC which specifically provides funding for vaccines for 92 low- and middle-income countries.

The COVAX pillar is working to accelerate R&D for promising vaccine candidates, manufacture doses at scale and deliver 2 billion doses globally by the end of 2021. CEPI, as a co-lead for the ACT Accelerator's Vaccines pillar, has agreements to support R&D for nine candidate vaccines, including the AstraZeneca and Novavax vaccine candidates.

The Bill & Melinda Gates Foundation, via its Strategic Investment Fund, will provide at-risk funding of US\$150 million to Gavi, which will be used to support the Serum Institute of India to manufacture potential vaccine candidates, and for future procurement of vaccines for low- and middle-income countries via Gavi's COVAX AMC.

The deal is additional to a Memorandum of Understanding between AstraZeneca and Gavi, announced in June, which will guarantee an additional 300 million doses of AstraZeneca's candidate vaccine to the wider COVAX Facility, to be supplied upon licensure or prequalification.

These two deals can help guarantee access to early doses for the most vulnerable on a truly global scale.

.....

### **[Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine](#)**

*Company working to ensure broad global access to COVID-19 vaccine candidate, following approval from regulators*

NEW BRUNSWICK, N.J., Aug. 5, 2020 /PRNewswire/ -- Johnson & Johnson (NYSE: [JNJ](#)) (the Company) today announced its Janssen Pharmaceutical Companies have entered into an agreement with the U.S. government for the large scale domestic manufacturing and delivery in the U.S. of 100 million doses of Janssen's SARS-CoV-2 investigational vaccine, Ad26.COV2.S, for use in the United States following approval or Emergency Use Authorization by the U.S. Food and Drug Administration (FDA).

The Biomedical Advanced Research and Development Authority ([BARDA](#)), part of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response, in collaboration with the U.S. Department of Defense, is committing over \$1 billion for this agreement. The vaccine will be provided at a global not-for-profit basis for emergency pandemic use. The U.S. government may also purchase an additional 200 million doses of Ad26.COV2.S under a subsequent agreement...

.....

.....

### **COVID-19 Vaccines – Discovery**

#### **[Novavax and Takeda Announce Collaboration for Novavax' COVID-19 Vaccine Candidate in Japan](#)**

August 07, 2020

***See NIH below in Announcements***

.....

.....

### **COVID-19 Vaccines – Manufacturing**

#### **[CEPI survey assesses potential COVID-19 vaccine manufacturing capacity](#)**

05 Aug 2020 By The CEPI Sustainable Manufacturing Team

One of the many challenges we are presented with by the COVID-19 pandemic is finding a way to meet the sheer scale of demand for a vaccine when it has been demonstrated to be safe and effective. We have to take a global view on what manufacturing capacity is available and to ensure we are investing in reserving such capacity now to avoid any delays in the manufacture and distribution of vaccines.

**To deliver on its mission CEPI has undertaken a survey of vaccine manufacturers to assess what capacity might be available to meet demand for a COVID-19 vaccine.**

## *CEPI's Sustainable Manufacturing Project*

In 2019, before the COVID-19 pandemic emerged, CEPI established a Sustainable Manufacturing Project to support the supply of CEPI's investigational vaccines to tackle epidemic events. The Sustainable Manufacturing Project, led by James Robinson, consisted of modelling the supply of vaccines (supply side), modelling the epidemiology of CEPI's [priority diseases](#) (demand side), evaluating potential manufacturing networks to secure capacity for manufacturing and stockpiling to ensure flexibility, affordability, and reliable supply. When COVID-19 emerged in early 2020, CEPI quickly pivoted this effort to focus on the pandemic response, so that we could quickly build a reliable evidence base for what facilities were potentially available for COVID-19 vaccine manufacture.

### *Survey of global COVID-19 vaccine manufacturing capacity*

**CEPI – in collaboration with the Bill & Melinda Gates Foundation, The Clinton Health Access Initiative, and PATH – undertook a broad, worldwide, [survey of vaccine manufacturers](#) to understand capabilities, capacities and interest in responding to the pandemic. We aimed to assess potential bottlenecks in the vaccine manufacturing and to work out what global capacity might be available to produce billions of doses of vaccine.**

Between April 3, and June 19, 2020, CEPI invited vaccine manufactures from around the world to take part in an anonymised survey to assess what manufacturing capacity was available to produce drug substance (ie, the unformulated active [immunogenic] substance) and drug product (ie, the finished dosage form of the product including final container) in the coming months, specifically between Oct 1, 2020, and Dec 31, 2021.

A key objective of this survey was to understand how COVID-19 vaccine manufacturing could be scaled up without affecting the manufacture of other important vaccines and to identify additional capacity in the global manufacturing system for both drug substance and drug product.

There is a risk that a few countries could monopolise global vaccine supply, limiting the supply of vaccines to those who need them most, as was the case with the [2009 flu pandemic](#). To truly end COVID-19 pandemic, it's crucial that the world works together to enable fair, global distribution of any vaccine.

In gathering these survey data, CEPI aims build a picture of the availability and global distribution of manufacturing capacity, which would inform how and where it could make strategic investments in vaccine manufacturing to ensure equitable access to any successful vaccine candidate.

### ***Key findings***

113 manufacturers, from over 30 countries, responded to our survey. 43 respondents were both drug-substance and drug-product manufacturers. 56 were drug-substance manufacturers only. 100 were drug-product manufacturers only.

**:: 2 to 4 billion doses :: Global capacity to produce COVID-19 vaccines through to end of year 2021**

**:: 113 :: Number of manufacturers who responded to the survey**

**:: 20% :: Proportion of the population who will be vaccinated in countries that participate in COVAX**

As reflected by the number of manufacturers with regulatory approvals for their operations, mature manufacturing capacity is available for both drug-substance and drug-product manufacturing in multiple locations around the world.

India has the largest production capacity for drug substance (specifically for microbial or yeast expression systems; recombinant protein from suspension cells; recombinant protein from insect cells; viruses; and DNA), followed by Europe and North America. Europe has the largest production capacity for RNA-based drug substance.

For drug product, the base-case estimates showed that China has the largest production capacity, followed by North America, and the rest of Asia and Oceania.

**Crucially, the survey data show that there is potential global capacity to produce at least 2-4 billion doses of COVID-19 vaccine through end of year 2021.** This finding is important for CEPI's wider COVID-19 response because – in collaboration with Gavi and WHO – we aim to distribute 2 billion doses of COVID-19 vaccine by the end of 2021 through a programme called COVAX. Vaccines manufactured and procured through COVAX will be delivered equally to all countries who participate in the initiative, proportional to their populations (initially prioritising healthcare workers then expanding to cover 20% of their population). **Our survey confirm that this 2 billion manufacturing target can not only be achieved but can be delivered without displacing other critical vaccine manufacturing activities.**

This analysis represents a snapshot in time from our survey responders and will have changed dramatically since the data was collected between May and June, 2020. To the best of our knowledge, this is the only publicly available data on global drug-substance and drug-product manufacturing capacity for vaccines gathered specifically during the early days of the pandemic.

CEPI has been and will continue to use this information in its COVID-19 pandemic response including matchmaking between vaccine developers and available capacity to maximise global capacity for COVID-19 vaccine manufacturing.

See survey results [here](#).

.....  
.....

## **Emergencies**

### **Ebola – DRC+**

*Public Health Emergency of International Concern (PHEIC)*

Last *WHO Situation Report* published [23 June 2020](#)

.....  
.....

## **Emergencies**

### **POLIO**

*Public Health Emergency of International Concern (PHEIC)*

### **Polio this week as of 5 August 2020**

***Summary of new WPV and cVDPV viruses this week (AFP cases and environmental samples):***

***:: Afghanistan:*** two WPV1 positive environmental samples

***:: Pakistan:*** three WPV1 cases, 12 WPV1 positive environmental samples and one cVDPV2 positive environmental sample

***:: Cameroon:*** one cVDPV2 case

***:: Chad:*** three cVDPV2 cases

***:: Democratic Republic of the Congo (DR Congo):*** two cVDPV2 cases

.....  
.....

### **WHO Grade 3 Emergencies** [to 8 Aug 2020]

Democratic Republic of the Congo - *No new digest announcements identified*

Mozambique floods - *No new digest announcements identified*

Nigeria - *No new digest announcements identified*

Somalia - *No new digest announcements identified*

South Sudan - *No new digest announcements identified*

Syrian Arab Republic - *No new digest announcements identified*

Yemen - *No new digest announcements identified*

.....

### **WHO Grade 2 Emergencies** [to 8 Aug 2020]

Afghanistan - *No new digest announcements identified*

Angola - *No new digest announcements identified*

Burkina Faso [in French] - *No new digest announcements identified*

Burundi - *No new digest announcements identified*

Cameroon - *No new digest announcements identified*

Central African Republic - *No new digest announcements identified*

Ethiopia - *No new digest announcements identified*

Iran floods 2019 - *No new digest announcements identified*

Iraq - *No new digest announcements identified*

Libya - *No new digest announcements identified*

Malawi - *No new digest announcements identified*

Measles in Europe - *No new digest announcements identified*

MERS-CoV - *No new digest announcements identified*  
Myanmar - *No new digest announcements identified*  
Niger - *No new digest announcements identified*  
occupied Palestinian territory - *No new digest announcements identified*  
HIV in Pakistan - *No new digest announcements identified*  
Sao Tome and Principe Necrotizing Cellulitis (2017) - *No new digest announcements identified*  
Sudan - *No new digest announcements identified*  
Ukraine - *No new digest announcements identified*  
Zimbabwe - *No new digest announcements identified*

.....

### **WHO Grade 1 Emergencies** [to 8 Aug 2020]

Chad - *No new digest announcements identified*  
Djibouti - *Page not responding at inquiry*  
Kenya - *No new digest announcements identified*  
Mali - *No new digest announcements identified*  
Namibia - viral hepatitis - *No new digest announcements identified*  
Tanzania - *No new digest announcements identified*

.....

.....

### **UN OCHA – L3 Emergencies**

*The UN and its humanitarian partners are currently responding to three 'L3' emergencies. This is the global humanitarian system's classification for the response to the most severe, large-scale humanitarian crises.*

#### **Syrian Arab Republic**

:: Syrian Arab Republic: COVID-19 Response Update No. 08 - 4 August 2020  
:: Recent Developments in Northwest Syria - Flash Update - As of 07 August 2020

#### **Yemen**

:: 05 August 2020 Yemen Humanitarian Update Issue 07 (July 2020)

.....

### **UN OCHA – Corporate Emergencies**

*When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.*

#### **East Africa Locust Infestation**

:: Desert Locust situation update - 7 August 2020

COVID-19 - *No new digest announcements identified*

.....

.....

### **WHO & Regional Offices** [to 8 Aug 2020]

5 August 2020 *News release*

[Plane carrying WHO trauma and surgical supplies arrives in Beirut, Lebanon](#)

.....

[Weekly Epidemiological Record, 7 August 2020, vol. 95, 32 \(pp. 369–380\)](#)

;; Lessons learnt in expediting prequalification and registration of Ebola Zaire vaccine

;; Monthly report on dracunculiasis cases, January-June 2020

.....

**WHO Regional Offices**

*Selected Press Releases, Announcements*

**WHO African Region AFRO**

*No new digest content identified*

**WHO Region of the Americas PAHO**

*No new digest content identified*

**WHO South-East Asia Region SEARO**

:: 7 August 2020 *News release*

[World breastfeeding week 2020: Focus on access to skilled support](#)

As the world marks Breastfeeding Week amidst the COVID-19 pandemic spread, WHO and partners are focusing on increasing mother's access to skilled breastfeeding support...

:: 6 August 2020 *News release*

[Maintain essential health services during COVID-19 response: WHO](#)

The World Health Organization urged Member countries in South-East Asia Region to maintain essential health and accelerate resumption of disrupted health-care services, hit by the...

**WHO European Region EURO**

:: [Patient guides build bridge between Syrian refugees and doctors in Turkey 07-08-2020](#)

:: [Epidemics and Public Health Emergency Operations Centre opens in North Macedonia 07-08-2020](#)

:: [New WHO tools to support health-care workers promoting breastfeeding in Europe 06-08-2020](#)

:: [Marko Obradovic: why new mothers need our support and why breastfeeding concerns us all 05-08-2020](#)

**WHO Eastern Mediterranean Region EMRO**

:: [WHO requires US\\$ 15 million to support immediate Beirut blast response and ensure vital health and disease prevention activities are maintained](#)

Cairo/Beirut, August 6, 2020 – As the public health impact of the Beirut blast becomes clearer, WHO is calling for US\$ 15 million to cover immediate emergency trauma and humanitarian health needs and ensure the continuity of the response to COVID-19 across the country. "We are particularly concerned about overburdened hospital and health workforce capacity, shortages of medicines and medical supplies, and the...

:: Statement by WHO's Regional Director on standing with the people of Lebanon following deadly Beirut blast

6 August 2020 – Even before the COVID-19 pandemic, our Region was plagued by emergencies. More than 70 million people were directly or indirectly affected by political conflict or natural disasters and in need of humanitarian aid. In the past 6 months, as the COVID-19 pandemic spread across the globe, the Region was impacted by another large-scale crisis that resulted in...

Plane carrying WHO trauma and surgical supplies arrives in Beirut, Lebanon

5 August 2020, Beirut, Lebanon – A plane carrying 20 tonnes of WHO health supplies has landed in Beirut, Lebanon, to support the treatment of patients injured by the massive blast that occurred in the city on 4 August. The supplies will cover 1000 trauma interventions and 1000 surgical interventions for people suffering from injuries and burns resulting from the...

### **WHO Western Pacific Region**

*No new digest content identified*

.....  
.....

**CDC/ACIP** [to 8 Aug 2020]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

*Latest News Releases*

**CDC Expects 2020 Outbreak of Life-Threatening Acute Flaccid Myelitis Transcript**

Tuesday, August 4, 2020

.....

**Africa CDC** [to 8 Aug 2020]

<http://www.africacdc.org/>

*News*

*Press Releases*

**World Mask Week aims to inspire global movement to wear face coverings in public**

6 August 2020

.....

**China CDC**

<http://www.chinacdc.cn/en/>

*No new digest content identified.*

**National Health Commission of the People's Republic of China**

<http://en.nhc.gov.cn/>

*News*

**Aug 8: Daily briefing on novel coronavirus cases in China**

On Aug 7, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 31 new cases of confirmed infections, 5 new cases of suspected infections, and no deaths.

### **Nation readies for fall, winter COVID-19 spikes**

2020-08-06

China is gearing up for a serious battle against the novel coronavirus in the fall and winter by building a more expansive and agile network of nucleic acid testing resources, officials said on Aug 5.

The country's current testing capacity is sufficient to cope with sporadic clusters of infections and meet demand for implementing regular disease control measures. More efforts will then be devoted to stepping up regional testing capabilities, increasing the number of mobile laboratories and accelerating development of rapid testing kits, according to officials.

The persistent drive to ramp up testing was recently stressed by the central government as health experts urged caution against potential COVID-19 outbreaks in fall and winter months, which could be worsened by the circulation of other contagious viruses—such as the seasonal flu—and gradual reopening of borders while the virus continues to rage globally.

"We should conduct a thorough evaluation of the transmission risk in fall and winter and step up preparedness in advance. It is better to have excessive stockpiles than face shortages," said Wang Jiangping, vice-minister of the Ministry of Industry and Technology Information...

### **WHO advance team to China concludes their mission: WHO chief**

2020-08-04

GENEVA - World Health Organization (WHO) chief said Monday that the WHO advance team that traveled to China has concluded their mission to lay the groundwork for further joint efforts to identify the virus origins.

"One of the areas that we've been continuing to study is the origins of the virus that causes COVID-19," WHO Director-General Tedros Adhanom Ghebreyesus told a virtual press conference from Geneva.

As a result of these efforts, he said that WHO and Chinese experts have drafted the Terms of Reference for the studies and program of work for an international team, led by WHO.

"The international team will include leading scientists and researchers from China and around the world," the WHO chief said...

.....  
.....

### **Announcements**

**Paul G. Allen Frontiers Group** [to 8 Aug 2020]

<https://alleninstitute.org/what-we-do/frontiers-group/news-press/>

*News*

### **Could treatments aimed at Alzheimer's disease help combat COVID-19?**

August 5, 2020

A team of cardiology researchers had a creative idea for a new way to treat dementia. Now they think it could help coronavirus patients too.

**BARDA – U.S. Department of HHS** [to 8 Aug 2020]

<https://www.phe.gov/about/barda/Pages/default.aspx>

*BARDA News*

[\*\*August 5, 2020: HHS, DOD Collaborate With Johnson & Johnson to Produce Millions of COVID-19 Investigational Vaccine Doses\*\*](#)

*[See Milestones above for detail]*

**BMGF - Gates Foundation** [to 8 Aug 2020]

<http://www.gatesfoundation.org/Media-Center/Press-Releases>

*No new digest content identified.*

**Bill & Melinda Gates Medical Research Institute** [to 8 Aug 2020]

<https://www.gatesmri.org/>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*

*No new digest content identified.*

**CARB-X** [to 8 Aug 2020]

<https://carb-x.org/>

*CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.*

*No new digest content identified.*

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 8 Aug 2020]

<http://cepi.net/>

*Latest News*

[\*\*CEPI survey assesses potential COVID-19 vaccine manufacturing capacity\*\*](#)

05 Aug 2020

By The CEPI Sustainable Manufacturing Team

*[See Milestones above for detail]*

**EDCTP** [to 8 Aug 2020]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*Latest news*

*No new digest content identified.*

**Emory Vaccine Center** [to 8 Aug 2020]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

**European Medicines Agency** [to 8 Aug 2020]

<http://www.ema.europa.eu/ema/>

*News & Press Releases*

*No new digest content identified.*

**European Vaccine Initiative** [to 8 Aug 2020]

<http://www.euvaccine.eu/>

*Latest News*

*No new digest content identified.*

**FDA** [to 8 Aug 2020]

<https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm>

*Press Announcements*

[August 7, 2020 - Coronavirus \(COVID-19\) Update: Daily Roundup August 7, 2020](#)

[August 6, 2020 - Coronavirus \(COVID-19\) Update: Daily Roundup August 6, 2020](#)

[August 5, 2020 - Coronavirus \(COVID-19\) Update: Daily Roundup August 5, 2020](#)

[August 4, 2020 - Coronavirus \(COVID-19\) Update: Daily Roundup August 4, 2020](#)

[August 3, 2020 - Coronavirus \(COVID-19\) Update: Daily Roundup August 3, 2020](#)

**Fondation Merieux** [to 8 Aug 2020]

<http://www.fondation-merieux.org/>

*News, Events*

*No new digest content identified.*

**Gavi** [to 8 Aug 2020]

<https://www.gavi.org/>

*News releases*

6 August 2020

**[Up to 100 million COVID-19 vaccine doses to be made available for low- and middle-income countries as early as 2021](#)**

*[See Milestones above for detail]*

**GHIT Fund** [to 8 Aug 2020]

<https://www.ghitfund.org/newsroom/press>

*GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that No new digest content identified.*

**Global Fund** [to 8 Aug 2020]

<https://www.theglobalfund.org/en/news/>

*Updates*

### **[The Global Fund Appoints Leading Global Health Experts to Head HIV, Tuberculosis and Malaria Teams](#)**

04 August 2020

The Global Fund has announced the appointment of three leading global health experts to head the organization's HIV, Tuberculosis and Malaria teams to accelerate action to fight the three diseases.

Siobhan Crowley has been appointed Head of HIV, Eliud Wandwalo as Head of Tuberculosis and Scott Filler as Head of Malaria.

In their new roles, the appointees will develop and expand highly effective teams of senior disease advisors with the primary role of supporting Global Fund country teams, strengthening collaboration and alignment on key opportunities across the Global Fund Secretariat and deepening technical partner engagement to strengthen in-country results...

**Hilleman Laboratories** [to 8 Aug 2020]

<http://www.hillemanlabs.org/>

*No new digest content identified.*

**Human Vaccines Project** [to 8 Aug 2020]

<http://www.humanvaccinesproject.org/media/press-releases/>

*Press Release*

### **[2020 Michelson Prizes Support Groundbreaking Research by Young Scientists](#)**

August 3, 2020 – The Michelson Medical Research Foundation and the Human Vaccines Project are pleased to announce the 2020 Michelson Prizes for Human Immunology and Vaccine Research and support the outstanding research of two young scientists advancing human immunology, vaccine discovery and immunotherapy across major global diseases.

We live in historic times. 2020 will be remembered as the year the world endured an unprecedented pandemic with vast implications on the entire global community. The COVID pandemic has highlighted the critical need for groundbreaking research in immunology and vaccine discovery. Now, more than ever, it is crucial to support and cultivate young scientists advancing the fields of immunology, vaccinology, and immunotherapy. That is why the Michelson Medical Research Foundation and the Human Vaccines Project engage in an annual international search to identify and support the most promising projects from young investigators.

**This year's winners are Danika Hill, a research fellow at Monash University, and Michael Birnbaum, assistant professor at MIT. They will be awarded the 2020 Michelson Prize for Human Immunology and Vaccine Research, receiving \$150,000 each...**

**IAVI** [to 8 Aug 2020]

<https://www.iavi.org/newsroom>

*Features*

*No new digest content identified.*

**International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

*No new digest content identified.*

**International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

*No new digest content identified.*

**IFFIm**

<http://www.iffim.org/>

*Announcements*

**[IFFIm issues NOK 2 billion in Vaccine Bonds for COVID-19 vaccine development](#)**

07 Jul 2020

IFFIm has issued NOK 2 billion in Vaccine Bonds to accelerate the availability of financing for urgent COVID-19 vaccine research and development by the Coalition for Epidemic Preparedness Innovations.

**IFRC** [to 8 Aug 2020]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Selected Press Releases, Announcements*

*Africa, South Africa*

**[South Africa: Lessons of HIV/AIDS key to halting COVID-19 slide, says Red Cross](#)**

Johannesburg/Geneva, 7 August 2020 – A senior Red Cross official has warned that South Africa needed to learn lessons from the country's fight against HIV/AIDS to help curb the rise in the number of people testing positive for COVID-19, as the number c ...

7 August 2020

*Asia Pacific, Bangladesh, India, Nepal*

**[17.5 million affected by floods and threatened by disease in South Asia](#)**

Dhaka/Kuala Lumpur, 6 August 2020 – Monsoon floods are robbing millions of people of their homes and livelihoods, with mounting risk of more deadly disease outbreaks when health resources are stretched to breaking point by COVID-19. So far almost 17.5 ...

6 August 2020

**IRC International Rescue Committee** [to 8 Aug 2020]

<http://www.rescue.org/press-release-index>

*Media highlights*

*Press Release*

**As confirmed COVID cases more than double in July across African countries, a lack of testing in crisis-affected contexts keeps responders in the dark about the real spread of the disease, warns IRC**

July 30, 2020

:: Each country in Africa where the IRC works has done less than 8,000 tests per million people, compared to the UK (205,782 per million), United Arab Emirates (472,590 per million), and Singapore (199,904 per million).

:: The countries in Africa where the IRC works which have done the least tests per million are Tanzania\* (63 tests per million), Niger (373 tests per million), Chad (383 tests per million, DRC (467 tests per million), and Burundi (563 tests per million).

:: The UK has done up to 550 times more tests per million than the countries in Africa where the IRC works.

:: The WHO recommends at least 1 test per 1,000 people per week - while countries like Niger and South Sudan have done 1 test per every 2,680 and 930 people in total respectively.

:: The WHO recommends countries have a test positivity rate of 5% or under for at least 14 days; Most African countries where the IRC works are not meeting this target, such as Somalia (32%), DRC (21%), South Sudan (18%), Cote d'Ivoire (17%) and CAR (16%).

:: Despite efforts to expand testing capacities, hard-hit countries need additional resources and support from the international community to expand testing and mitigate the spread of COVID-19.

**IVAC** [to 8 Aug 2020]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates*

**DoVE Return on Investment (ROI) Publication Launch**

August 2020

The Decade of Vaccine Economics (DoVE) Project, carried out by the Johns Hopkins Bloomberg School of Public Health's International Vaccine Access Center (IVAC) for nearly ten years, has computed the return-on-investment for vaccines preventing 10 infectious diseases in 73 countries that have received support from Gavi, the Vaccine Alliance.

**IVI** [to 8 Aug 2020]

<http://www.ivi.int/>

*Selected IVI News & Announcements*

*No new digest content identified.*

**JEE Alliance** [to 8 Aug 2020]

<https://www.jeealliance.org/>

*Selected News and Events*

*No new digest content identified.*

**MSF/Médecins Sans Frontières** [to 8 Aug 2020]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Lebanon*

**[MSF supporting Beirut's health services in wake of massive blast](#)**

Project Update 6 Aug 2020

*Mediterranean migration*

**[MSF and Sea-Watch announce collaboration to save lives at sea](#)**

Press Release 6 Aug 2020

*South Africa*

**[Western Cape begins to breathe after COVID-19 peak](#)**

Project Update 6 Aug 2020

*Iraq*

**[Mosul: MSF works on dual front of COVID-19 and lifesaving medical care](#)**

Project Update 5 Aug 2020

**[Brazil](#)**

**[Chasing COVID-19 in the Brazilian Amazon](#)**

Exposure.co 4 Aug 2020

**National Vaccine Program Office - U.S. HHS** [to 8 Aug 2020]

<https://www.hhs.gov/vaccines/about/index.html>

*NVAC Meetings*

**[September 23-24, 2020 Meeting \(Virtual\)](#)**

**[February 4-5, 2021 NVAC Meeting](#)**

**[June 16-17, 2021 NVAC Meeting](#)**

**NIH** [to 8 Aug 2020]

<http://www.nih.gov/news-events/news-releases>

*Selected News Releases*

Friday, August 7, 2020

**[NIH-funded project seeks to identify children at risk for MIS-C](#)**

*Research effort will develop tests to predict severe COVID-19-linked illness.*

The National Institutes of Health has announced research funding to encourage the development of approaches that identify children at high risk for developing Multisystem Inflammatory Syndrome in Children (MIS-C), thought to be a severe complication of COVID-19. Up to \$20 million will be awarded to successful research proposals over four years.

Most children exposed to or infected with SARS-CoV-2, the virus that causes COVID-19, develop only a mild form of the illness. However, others go on to develop [MIS-C\(link is external\)](#), a severe, sometimes fatal, inflammation of organs and tissues, including the heart, lungs, kidneys, brain, skin and eyes. The new effort seeks to encourage studies of genetic,

immune, viral, environmental, and other factors that influence how severe a case of COVID-19 will be and the chances of developing to MIS-C.

“We urgently need methods to distinguish children at high risk for MIS-C from those unlikely to experience major ill effects from the virus, so that we can develop early interventions to improve their outcomes,” said Diana W. Bianchi, M.D., director of NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)...

Thursday, August 6, 2020

### **[NIH clinical trial testing remdesivir plus interferon beta-1a for COVID-19 treatment begins](#)**

A randomized, controlled clinical trial evaluating the safety and efficacy of a treatment regimen consisting of the antiviral remdesivir plus the immunomodulator interferon beta-1a in patients with coronavirus disease 2019 (COVID-19) has begun. The study, called the Adaptive COVID-19 Treatment Trial 3 (ACTT 3), is anticipated to enroll more than 1,000 hospitalized adults with COVID-19 at as many as 100 sites in the United States and abroad. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the trial...

Wednesday, August 5, 2020

### **[NIH harnesses AI for COVID-19 diagnosis, treatment, and monitoring](#)**

*Collaborative network to enlist medical imaging and clinical data sciences to reveal unique features of COVID-19.*

The National Institutes of Health has launched the Medical Imaging and Data Resource Center (MIDRC), an ambitious effort that will harness the power of artificial intelligence and medical imaging to fight COVID-19. The multi-institutional collaboration, led by the National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of NIH, will create new tools that physicians can use for early detection and personalized therapies for COVID-19 patients.

“This program is particularly exciting because it will give us new ways to rapidly turn scientific findings into practical imaging tools that benefit COVID-19 patients,” said Bruce J. Tromberg, Ph.D., NIBIB Director. “It unites leaders in medical imaging and artificial intelligence from academia, professional societies, industry, and government to take on this important challenge.”

The features of infected lungs and hearts seen on medical images can help assess disease severity, predict response to treatment, and improve patient outcomes. However, a major challenge is to rapidly and accurately identify these signatures and evaluate this information in combination with many other clinical symptoms and tests. The MIDRC goals are to lead the development and implementation of new diagnostics, including machine learning algorithms, that will allow rapid and accurate assessment of disease status and help physicians optimize patient treatment.

“This effort will gather a large repository of COVID-19 chest images,” explained Guoying Liu, Ph.D., the NIBIB scientific program lead on this effort, “allowing researchers to evaluate both lung and cardiac tissue data, ask critical research questions, and develop predictive COVID-19 imaging signatures that can be delivered to healthcare providers.”...

### **[NIH-Moderna investigational COVID-19 vaccine shows promise in mouse studies](#)**

August 5, 2020 — Vaccine currently being evaluated in Phase 3 clinical testing.

**[NIH clinical trial to test antibodies and other experimental therapeutics for mild and moderate COVID-19](#)**

August 4, 2020 — Initial trial to determine if monoclonal antibodies can shorten severity of COVID-19 in outpatients.

**[NIH launches clinical trial to test antibody treatment in hospitalized COVID-19 patients](#)**

August 4, 2020 — Study aims to determine safety and efficacy of experimental monoclonal antibodies.

**PATH** [to 8 Aug 2020]

<https://www.path.org/media-center/>

*No new digest content identified.*

**Sabin Vaccine Institute** [to 8 Aug 2020]

<http://www.sabin.org/updates/pressreleases>

*Statements and Press Releases*

*No new digest content identified.*

**UNAIDS** [to 8 Aug 2020]

<http://www.unaids.org/en>

*Selected Press Releases/Reports/Statements*

4 August 2020

**[Virtual training for antiretroviral therapy prescribers launched in Papua New Guinea](#)**

**UNICEF** [to 8 Aug 2020]

<https://www.unicef.org/media/press-releases>

*Selected Press releases/Announcements*

*Press release*

08/07/2020

**[UNICEF loses life-saving supplies in Kinshasa warehouse fire](#)**

*Press release*

08/07/2020

**[Geneva Palais briefing note on situation for children affected by Beirut explosions and UNICEF response](#)**

*Press release*

08/06/2020

**[80,000 children displaced due to Beirut explosions – UNICEF](#)**

UNICEF scales up response and assistance to children and families

*Statement*

08/05/2020

**[UNICEF sad and shocked at Beirut explosions, concerned about the wellbeing of children, and supporting partners on the ground](#)**

Statement from Ms. Yukie Mokuo, UNICEF Representative in Lebanon

*Press release*

08/04/2020

**[UNICEF condemns attack in Cameroon's Far North that reportedly killed 10 children](#)**

*Statement*

08/03/2020

**[Support breastfeeding for a healthier planet](#)**

Joint message for World Breastfeeding Week 2020 by UNICEF Executive Director Henrietta H. Fore and WHO Director-General Tedros Adhanom Ghebreyesus

*Press release*

08/03/2020

**[Children in Central America and the Caribbean facing dual threat of stronger hurricane season and COVID-19](#)**

Displacement and service interruption caused by storms could leave children and families more vulnerable to virus, UNICEF warns

**Unitaid** [to 8 Aug 2020]

<https://unitaid.org/>

*Featured News*

*No new digest content identified.*

**Vaccination Acceptance Research Network (VARN)** [to 8 Aug 2020]

<https://vaccineacceptance.org/news.html#header1-2r>

*Announcements*

*No new digest content identified.*

**Vaccine Confidence Project** [to 8 Aug 2020]

<http://www.vaccineconfidence.org/>

*Research and Reports*

**[Cross-Country Comparison of Public Awareness, Rumors, and Behavioral Responses to the COVID-19 Epidemic: Infodemiology Study](#)**

4 Aug 2020

**Vaccine Education Center – Children's Hospital of Philadelphia** [to 8 Aug 2020]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*No new digest content identified.*

**Wellcome Trust** [to 8 Aug 2020]

<https://wellcome.ac.uk/news>  
*No new digest content identified.*

**The Wistar Institute** [to 8 Aug 2020]  
<https://www.wistar.org/news/press-releases>  
*Press Releases*  
*No new digest content identified.*

**WFPHA: World Federation of Public Health Associations** [to 8 Aug 2020]  
<https://www.wfpha.org/>  
*Latest News*  
*No new digest content identified.*

**World Organisation for Animal Health (OIE)** [to 8 Aug 2020]  
<https://www.oie.int/en/for-the-media/press-releases/2020/>  
*No new digest content identified.*

.....

**ARM [Alliance for Regenerative Medicine]** [to 8 Aug 2020]  
<https://alliancerm.org/press-releases/>  
*Press Releases*  
**[New Report: Regenerative Medicine & Advanced Therapies Sector Thriving Despite COVID-19](#)**

August 6, 2020  
Washington, DC

The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, today announces the publication of its H1 2020 Global Sector Report, "Innovation in the Time of COVID-19." The report provides an in-depth look at trends and metrics in the gene, cell, and tissue-based therapeutic sector in the midst of the pandemic.

**BIO** [to 8 Aug 2020]  
<https://www.bio.org/press-releases>  
*Press Releases*  
**[Ensuring Scientific Justice by Building Bridges to Minority Communities is Centerpiece of BIOEquality Agenda](#)**

August 6, 2020

New focus on justice through equity in diverse clinical trials, STEM education and expanding entrepreneurship to undeserved communities will drive nation's largest life science advocacy organization The Biotechnology Innovation Organization (BIO)...

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 8 Aug 2020]

<http://www.dcvmn.org/>

*News; Upcoming events*

**[Gavi/UNICEF SD information session on COVAX Facility](#)**

August 12th, 2020 13:00 - 15:30 CET

**ICBA – International Council of Biotechnology Associations** [to 8 Aug 2020]

<https://internationalbiotech.org/>

*News*

*No new digest content identified.*

**IFPMA** [to 8 Aug 2020]

<http://www.ifpma.org/resources/news-releases/>

*Selected Press Releases, Statements, Publications*

*No new digest content identified.*

**PhRMA** [to 8 Aug 2020]

<http://www.phrma.org/>

*Selected Press Releases, Statements*

*Press Release*

**[PhRMA Statement on the “Buy American” Executive Order](#)**

WASHINGTON, D.C. (August 6, 2020) – Pharmaceutical Research and Manufacturers of America President and CEO Stephen J. Ubl made the following statement:

“At a time when our nation’s priority should be to beat COVID-19, President Trump today signed yet another executive order that creates even more barriers to ongoing biopharmaceutical manufacturing and innovation. Companies are working around the clock to research and develop treatments and a vaccine for COVID-19. At the same time, they are working to ensure they have the capacity to manufacture the treatments and vaccines once approved so that every patient that needs them has access to them. These efforts are all hands on deck for the biopharmaceutical industry but each executive order issued by the administration adds another roadblock, making it harder to fight this pandemic.

“The administration is forcing biopharmaceutical companies to shift their critical attention and resources away from COVID-19 work to focus on making substantial changes to their business models necessary to comply with this and other recent executive orders. Increasing U.S. manufacturing of medicines is a laudable goal, but it cannot happen overnight and should not come at the expense of medical innovation or Americans’ access to the medicines they need.

“The recent executive orders also contradict and undermine each other, creating chaos in an industry that is on the frontlines of fighting COVID-19. With today’s ‘Buy American’ executive order, the administration effectively is taking the unprecedented step of mandating manufacturing of medicines in the United States. Yet at the same time, through the ‘most favored nation’ executive order, the administration is creating a huge disincentive to invest in U.S. biopharmaceutical research and manufacturing. Together, the result is less investment in U.S. innovation and the potential for major long-term supply chain disruptions – the opposite of

what America needs right now. None of these executive orders will help patients access or afford their medicines.

“The ‘Buy American’ executive order could disrupt the global pharmaceutical supply chain, jeopardizing our ability to respond to the current crisis and potentially leading to major long-term supply chain disruptions, including shortages. Rather than government mandates, we should look for policies that enable more domestic manufacturing without putting the stability of pharmaceutical supply chains at risk.”

### **Industry Watch** [to 8 Aug 2020]

#### **[GSK launches national public awareness campaign to reverse steep decline in already low immunization rates for adults](#)**

PHILADELPHIA, Aug. 5, 2020 /PRNewswire/ -- GSK today launched a national campaign to help increase low rates of vaccination among older adults. The campaign, Brought to You By Vaccines, will educate adults ages 50 and older about the value of vaccines and the urgent need to talk to their healthcare provider or pharmacist about the recommended vaccines they need or may have recently missed...

\* \* \* \*

### **Journal Watch**

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

### **American Journal of Infection Control**

August 2020 Volume 48, Issue 8, p859-974

<http://www.ajicjournal.org/current>

[Reviewed earlier]

### **American Journal of Preventive Medicine**

August 2020 Volume 59, Issue 2, p149-308

<http://www.ajpmonline.org/current>

[Reviewed earlier]

### **American Journal of Public Health**

August 2020 110(8)

<http://ajph.aphapublications.org/toc/ajph/current>  
[Reviewed earlier]

**American Journal of Tropical Medicine and Hygiene**

Volume 103, Issue 1, July 2020

<http://www.ajtmh.org/content/journals/14761645/103/1>

[Reviewed earlier]

**Annals of Internal Medicine**

21 July 2020 Volume 173, Issue 2

<http://annals.org/aim/issue>

[Reviewed earlier]

**Artificial Intelligence – An International Journal**

Volume 285 August 2020

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/285/suppl/C>

[Reviewed earlier]

**BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 8 Aug 2020)

[No new digest content identified]

**BMJ Global Health**

August 2020 - Volume 5 - 8

<https://gh.bmj.com/content/5/8>

*Commentary*

[\*\*Patient-centric research in the time of COVID-19: conducting ethical COVID-19 research in Africa\*\*](#) (6 August, 2020)

Victoria Nembaware, Nchangwi Syntia Munung, Alice Matimba, Nicki Tiffin

*Original research*

[\*\*A checklist to improve health system resilience to infectious disease outbreaks and natural hazards\*\*](#) (5 August, 2020)

Diane Meyer, David Bishai, Sanjana J Ravi, Harunor Rashid, Shehrin Shaila Mahmood, Eric Toner, Jennifer B Nuzzo

*Practice*

[\*\*How to set up government-led national hygiene communication campaigns to combat COVID-19: a strategic blueprint\*\*](#) (6 August, 2020)

Val Curtis, Robert Dreibelbis, Myriam Sidibe, Jason Cardosi, Jennifer Sara, Chris Bonell, Kaposo Mwambuli, Soma Ghosh Moulik, Sian White, Robert Aunger

### **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 8 Aug 2020)

[No new digest content identified]

### **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 8 Aug 2020)

[No new digest content identified]

### **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 8 Aug 2020)

[No new digest content identified]

### **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 8 Aug 2020)

[No new digest content identified]

### **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 8 Aug 2020)

[No new digest content identified]

### **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 8 Aug 2020)

#### **[Introduction of multi-dose PCV 13 vaccine in Benin: from the decision to vaccinators experience](#)**

*In 2011, Benin introduced the 13-valent pneumococcal conjugated vaccine (PCV13), in a single-dose vial, into its Expanded Programme for Immunisation (EPI) with support from Gavi. In April 2018, with the support of the Agence de Médecine Préventive Afrique (AMP) and other technical and financial partners, the single-dose vial was transitioned to a four-dose vial. Here we describe the decision-making process and the experience of the vaccinators during the change.*

Authors: Daleb Abdoulaye Alfa, Roch A. Hounghinin, G. Patrick Ilboudo, Naomi Dick, Landry Kaucley and Téné-Alima Esoh

Citation: BMC Public Health 2020 20:1216

Content type: Research article

Published on: 8 August 2020

**BMC Research Notes**

<http://www.biomedcentral.com/bmcresearchnotes/content>

(Accessed 8 Aug 2020)

[No new digest content identified]

**BMJ Open**

August 2020 - Volume 10 - 8

<https://bmjopen.bmj.com/content/10/8?current-issue=y>

[New issue; No digest content identified]

**Bulletin of the World Health Organization**

Volume 98, Number 8, August 2020, 509-580

<https://www.who.int/bulletin/volumes/98/8/en/>

[Reviewed earlier]

**Child Care, Health and Development**

Volume 46, Issue 5 Pages: 537-649 September 2020

<https://onlinelibrary.wiley.com/toc/13652214/current>

[New issue; No digest content identified]

**Clinical Pharmacology & Therapeutics**

Volume 108, Issue 1 Pages: 1-161 July 2020

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/2020/108/1>

[Reviewed earlier]

**Clinical Therapeutics**

June 2020 Volume 42, Issue 6, p959-1136, e101-e114

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

**Clinical Trials**

Volume 17 Issue 3, June 2020

<https://journals.sagepub.com/toc/ctja/17/3>

[Reviewed earlier]

**Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 8 Aug 2020]

[No new digest content identified]

### **Contemporary Clinical Trials**

Volume 94 July 2020

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/94/suppl/C>

[New issue; No digest content identified]

### **The CRISPR Journal**

Volume 3, Issue 3 / June 2020

<https://www.liebertpub.com/toc/crispr/3/3>

[Reviewed earlier]

### **Current Genetic Medicine Reports**

Volume 8, Issue 2, June 2020

<https://link.springer.com/journal/40142/8/2>

[Reviewed earlier]

### **Current Opinion in Infectious Diseases**

August 2020 - Volume 33 - Issue 4

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[Reviewed earlier]

### **Developing World Bioethics**

Volume 20, Issue 2 Pages: 61-114 June 2020

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

### **Development in Practice**

Volume 30, Issue 4, 2020

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

### **Disaster Medicine and Public Health Preparedness**

Volume 14 - Issue 2 - April 2020

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

### **Disasters**

Volume 44, Issue 3 Pages: 433-618 July 2020

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

## **EMBO Reports**

Volume 21 Issue 8 5 August 2020

<https://www.embopress.org/toc/14693178/current>

*Science & Society* 27 July 2020

### **[The moral status of human embryo-like structures: potentiality matters? : The moral status of human synthetic embryos](#)**

Tsutomu Sawai et al

New techniques to generate and culture embryo-like structures from stem cells require a more fine-grained distinction of potential to define the moral status of these structures.

## **Emerging Infectious Diseases**

Volume 26, Number 8—August 2020

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

## **Epidemics**

Volume 31 June 2020

<https://www.sciencedirect.com/journal/epidemics/vol/31/suppl/C>

[Reviewed earlier]

## **Epidemiology and Infection**

Volume 148 - 2020

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

## **Ethics & Human Research**

Volume 42, Issue 4 Pages: 1-40 July–August 2020

<https://onlinelibrary.wiley.com/toc/25782363/current>

***Pregnant Women Covid-19 Vaccine Challenge Trials Lotteries***

[Reviewed earlier]

## **The European Journal of Public Health**

Volume 30, Issue Supplement\_2, June 2020

[https://academic.oup.com/eurpub/issue/30/Supplement\\_2](https://academic.oup.com/eurpub/issue/30/Supplement_2)

[Reviewed earlier]

## **Expert Review of Vaccines**

Vol 19 (6) 2020

<https://www.tandfonline.com/toc/ierv20/current>

*Review*

## **[Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication](#)**

Kimberly M. Thompson & Dominika A. Kalkowska

Received 28 Feb 2020, Accepted 22 Jun 2020, Published online: 08 Aug 2020

### ***ABSTRACT***

#### **Introduction**

Over the last 20 years (2000-2019) the partners of the Global Polio Eradication Initiative (GPEI) invested in the development and application of mathematical models of poliovirus transmission as well as economics, policy, and risk analyses of polio endgame risk management options, including policies related to poliovirus vaccine use during the polio endgame.

#### **Areas covered**

This review provides a historical record of the polio studies published by the three modeling groups that primarily performed the bulk of this work. This review also systematically evaluates the polio transmission and health economic modeling papers published in English in peer-reviewed journals from 2000 to 2019, highlights differences in approaches and methods, shows the geographic coverage of the transmission modeling performed, identified common themes, and discusses instances of similar or conflicting insights or recommendations.

#### **Expert opinion**

Polio modeling performed during the last 20 years substantially impacted polio vaccine choices, immunization policies, and the polio eradication pathway. As the polio endgame continues, national preferences for polio vaccine formulations and immunization strategies will likely continue to change. Future modeling will likely provide important insights about their cost-effectiveness and their relative benefits with respect to controlling polio and potentially achieving and maintaining eradication.

### **Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 8 Aug 2020]

[No new digest content identified]

### **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 8 Aug 2020]

[No new digest content identified]

### **Global Health Action**

Volume 12, 2019 Issue 1

<https://www.tandfonline.com/toc/zgha20/12/sup1?nav=toCList>

[Reviewed earlier]

### **Global Health: Science and Practice (GHSP)**

2020 | Volume 8 | Number 2 June 30, 2020

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

## **Global Public Health**

Volume 15, 2020 Issue 8

<http://www.tandfonline.com/toc/rgph20/current>

[Reviewed earlier]

## **Globalization and Health**

<http://www.globalizationandhealth.com/>

### **Promoting the use of evidence in health policymaking in the ECOWAS region: the development and contextualization of an evidence-based policymaking guidance**

*The Economic Commission of the West African States (ECOWAS), through her specialised health Institution, the West African Health Organization (WAHO) is supporting Members States to improve health outcomes in West Africa. There is a global recognition that evidence-based health policies are vital towards achieving continued improvement in health outcomes. The need to have a tool that will provide systematic guide on the use of evidence in policymaking necessitated the production of the evidence-based policy-making (EBPM) Guidance.*

Authors: Chigozie Jesse Uneke, Issiaka Sombie, Ermel Johnson, Bilikis Iyabo Uneke and Stanley Okolo

Content type: Research

6 August 2020

## **Health Affairs**

Vol. 39, No. 7 July 2020

<https://www.healthaffairs.org/toc/hlthaff/current>

### ***Food, Income, Work & More***

[Reviewed earlier]

## **Health and Human Rights**

Volume 22, Issue 1, June 2020

<https://www.hhrjournal.org/volume-22-issue-1-june-2020/>

### ***Special Section: Mental Health and Human Rights***

[Reviewed earlier]

## **Health Economics, Policy and Law**

Volume 15 - Issue 3 - July 2020

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

## **Health Policy and Planning**

Volume 35, Issue 6, July 2020

<https://academic.oup.com/heapol/issue/35/6>

[Reviewed earlier]

## **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 8 Aug 2020]

[No new digest content identified]

## **Human Gene Therapy**

Volume 31, Issue 13-14 / July 2020

<https://www.liebertpub.com/toc/hum/31/13-14>

### ***Focus on Retinal Gene Therapy***

[New issue; No digest content identified]

## **Humanitarian Exchange Magazine**

Number 77, March 2020

<https://odihpn.org/magazine/responding-to-ebola-in-the-democratic-republic-of-congo/>

### ***Responding to Ebola in the Democratic Republic of Congo***

by Humanitarian Practice Network

This edition of Humanitarian Exchange, co-edited with Anne Harmer, focuses on the response to the Ebola outbreak in the Democratic Republic of Congo (DRC). Although at the time of publication the outbreak appeared to have ended, over its course it claimed 2,200 lives, with more than 3,300 infected, making this the world's second largest outbreak ever.

In the lead article, Natalie Roberts reflects on the extent to which humanitarian actors have applied learning from the outbreak in West Africa in 2014–2016. Richard Kojan and colleagues report on the NGO ALIMA's flexible, patient-centred approach to reducing mortality, Marcela Ascuntar reflects on lessons learned from community feedback and Bernard Balibuno, Emanuel Mbuna Badjonga and Howard Mollett highlight the crucial role faith-based organisations have played in the response. In their article, Theresa Jones, Noé Kasali and Olivia Tulloch outline the work of the Bethesda counselling centre in Beni, which provides support to grieving families. Reflecting on findings from a recent assessment by Translators without Borders, Ellie Kemp describes the challenges involved in providing clear and accessible information on Ebola and the response, and Sung Joon Park and colleagues explain how humane care and treatment can help increase trust and confidence in the response. Stephen Mugamba and his co-authors highlight the importance of community involvement in Ebola research, and Gillian McKay and her co-authors examine the impact of the Ebola outbreak and response on sexual and reproductive health services.

Stacey Mearns, Kiryn Lanning and Michelle Gayer present an Ebola Readiness Roadmap to support NGOs in preparing for an outbreak, while Edward Kumakech, Maurice Sadlier, Aidan Sinnott and Dan Irvine report on a Gap Analysis tool looking at the communication, community engagement and compliance tracking activities that need to be in place before an Ebola vaccine is deployed. Emanuele Bruni and colleagues describe the development of a new monitoring and evaluation framework for strategic response planning. The edition ends with an article by Adelia Fairbanks, who argues for an acceptance strategy in the DRC to improve security and access for responding agencies.

**Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 16, Issue 7, 2020

<http://www.tandfonline.com/toc/khvi20/current>

*Article*

**[ASVAC2019: 7th Asian Vaccine Conference](#)**

Kyaw Linn, Lulu Bravo, Daniel Yam Thiam Goh & E. Anthony S. Nelson

Pages: 1476-1484

Published online: 06 Jan 2020

*Article*

**[Inequality in measles vaccination coverage in the “big six” countries of the WHO South-East Asia region](#)**

Yaqing Gao, Ashish Kc, Chunyi Chen, Yue Huang, Yinping Wang, Siyu Zou & Hong Zhou

Pages: 1485-1497

Published online: 09 Apr 2020

*Review*

**[Vaccination coverage and vaccine hesitancy among vulnerable population of India](#)**

Karpaga Priya P., Vineet Kumar Pathak & Anjan Kumar Giri

Pages: 1502-1507

Published online: 04 Feb 2020

*Article*

**[Vaccine hesitancy and the resurgence of vaccine preventable diseases: the way forward for Malaysia, a Southeast Asian country](#)**

L. P. Wong, P. F. Wong & S. AbuBakar

Pages: 1511-1520

Published online: 24 Jan 2020

*Article*

**[Multidimensional social and cultural norms influencing HPV vaccine hesitancy in Asia](#)**

Li Ping Wong, Pooi-Fong Wong, Megat Mohamad Amirul Amzar Megat Hashim, Liyuan Han, Yulan Lin, Zhijian Hu, Qinjian Zhao & Gregory D. Zimet

Pages: 1611-1622

Published online: 19 May 2020

*Article*

**[Fathers’ participation in the HPV vaccination decision-making process doesn’t increase parents’ intention to make daughters get the vaccine](#)**

Tomomi Egawa-Takata, Ruriko Nakae, Mariko Shindo, Ai Miyoshi, Tsuyoshi Takiuchi, Takashi Miyatake & Tadashi Kimura

Pages: 1653-1658

Published online: 09 Jan 2020

*Article*

**[Landscape of vaccine access and health technology assessment role in decision-making process in ASEAN countries](#)**

Suthira Taychakhoonavudh, Woralak Chumchujan, Raymond Hutubessy & Nathorn Chaiyakunapruk

Pages: 1728-1737

Published online: 23 Jun 2020

**Infectious Agents and Cancer**

<http://www.infectagentscancer.com/content>

[Accessed 8 Aug 2020]

[No new digest content identified]

**Infectious Diseases of Poverty**

<http://www.idpjournal.com/content>

[Accessed 8 Aug 2020]

[No new digest content identified]

**International Health**

Volume 12, Issue 4, July 2020

<https://academic.oup.com/inthealth/issue/12/4>

[Reviewed earlier]

**International Journal of Community Medicine and Public Health**

Vol 7, No 7 (2020) July 2020

<https://www.ijcmph.com/index.php/ijcmph/issue/view/64>

[Reviewed earlier]

**International Journal of Epidemiology**

Volume 49, Issue 3, June 2020

<https://academic.oup.com/ije/issue/49/3>

*Opinion*

**[The SARS, MERS and novel coronavirus \(COVID-19\) epidemics, the newest and biggest global health threats: what lessons have we learned?](#)**

Noah C Peeri, Nistha Shrestha, Md Siddikur Rahman, Rafdzah Zaki, Zhengqi Tan ...

**International Journal of Human Rights in Healthcare**

Volume 13 Issue 3 2020

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/13/iss/3>

*Table of Contents*

[Reviewed earlier]

## **International Journal of Infectious Diseases**

July 2020 Volume 96, p1-714

[https://www.ijidonline.com/issue/S1201-9712\(20\)X0008-7](https://www.ijidonline.com/issue/S1201-9712(20)X0008-7)

[Reviewed earlier]

## **JAMA Network**

**[COVID-19 Update](#)** August 1, 2020

*These articles on COVID-19 were published across the JAMA Network in the last week.*

## **JAMA**

August 4, 2020, Vol 324, No. 5, Pages 419-524

<https://jamanetwork.com/journals/jama/currentissue>

*Original Investigation*

### **[Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial](#)**

Ling Li, MD, PhD; Wei Zhang, MD; Yu Hu, MD, PhD; et al.

has active quiz has multimedia has audio

JAMA. 2020;324(5):460-470. doi:10.1001/jama.2020.10044

This randomized trial compares the effects of convalescent plasma therapy with standard care vs standard care alone on time to clinical improvement among patients with severe or life-threatening COVID-19 disease in China.

### **[Developing a SARS-CoV-2 Vaccine at Warp Speed](#)**

Kevin P. O’Callaghan, MB, BCh, BAO; Allison M. Blatz, MD; Paul A. Offit, MD

free access has active quiz has multimedia has audio

JAMA. 2020;324(5):437-438. doi:10.1001/jama.2020.12190

This Viewpoint discusses the mechanisms of the 5 leading COVID-19 vaccine candidates—2 messenger RNA vaccines, 1 recombinant VSV vector product, and 2 replication-defective adenovirus vector approaches—and emphasizes the need to demonstrate safety as well as efficacy to facilitate broad uptake by the public.

#### *Conclusions*

As the COVID-19 pandemic continues to cause significant disruption to both the physical and economic health of the world’s population, pathways of vaccine development are adapting in ways that could not have been predicted even a year ago. The rapid identification of immunogenic targets of a novel coronavirus, the leveraging of experimental vaccine platforms, and the tragic nature of an ongoing pandemic have created a fertile breeding ground for innovation. Although the ultimate success of a vaccine candidate, or candidates, remains unknown, the changes in the field of vaccinology that these exigent circumstances have brought are likely here to stay.

:: [Audio Author Interview: Coronavirus Vaccine Development](#)

:: [Conversations with Dr Bauchner: Coronavirus Update With Eric Topol, MD](#)

### **[The Development of COVID-19 Vaccines - Safeguards Needed](#)**

Nicole Lurie, MD, MSPH; Joshua M. Sharfstein, MD; Jesse L. Goodman, MD, MPH

free access has multimedia has audio

JAMA. 2020;324(5):439-440. doi:10.1001/jama.2020.12461

This Viewpoint lists 4 safeguards policy makers should consider before release of a COVID-19 vaccine, including ensuring effectiveness through clinical trials, providing evidence of safety, requiring informed consent before vaccination, and establishing comprehensive adverse effects monitoring systems.

:: [Audio Highlights](#)

free access online only has audio

### **[Communicating Science in the Time of a Pandemic](#)**

Richard Saitz, MD, MPH; Gary Schwitzer

free access has active quiz has multimedia has audio

JAMA. 2020;324(5):443-444. doi:10.1001/jama.2020.12535

This Viewpoint uses the example of rapid changes to public reporting on the efficacy of hydroxychloroquine and remdesivir for COVID-19 to illustrate how misinformation damages the public's trust in science and medicine, and urges accuracy and circumspection in news reports of developments in the pandemic.

### **JAMA Pediatrics**

August 2020, Vol 174, No. 8, Pages 741-812

<http://archpedi.jamanetwork.com/issue.aspx>

[New issue; No digest content identified]

### **JBI Database of Systematic Review and Implementation Reports**

July 2020 - Volume 18 - Issue 7

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

### **Journal of Adolescent Health**

August 2020 Volume 67, Issue 2, p145-308

[https://www.jahonline.org/issue/S1054-139X\(20\)X0007-3](https://www.jahonline.org/issue/S1054-139X(20)X0007-3)

[Reviewed earlier]

### **Journal of Artificial Intelligence Research**

Vol. 68 (2020)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

### **Journal of Community Health**

Volume 45, Issue 4, August 2020

<https://link.springer.com/journal/10900/45/4>

[Reviewed earlier]

### **Journal of Development Economics**

Volume 145 June 2020

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/145/suppl/C>

[Reviewed earlier]

**Journal of Empirical Research on Human Research Ethics**

Volume 15 Issue 3, July 2020

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

**Journal of Epidemiology & Community Health**

August 2020 - Volume 74 - 8

<https://jech.bmj.com/content/74/8>

[Reviewed earlier]

**Journal of Evidence-Based Medicine**

Volume 13, Issue 2 Pages: 89-177 May 2020

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

**Journal of Global Ethics**

Volume 16, Issue 1, 2020

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 31, Number 2, May 2020

<https://muse.jhu.edu/issue/42391>

[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 22, Issue 4, August 2020

<https://link.springer.com/journal/10903/22/4>

[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 18, 2020\_ Issue 3

<https://www.tandfonline.com/toc/wimm20/current>

[New issue; No digest content identified]

**Journal of Infectious Diseases**

Volume 222, Issue 3, 1 August 2020  
<https://academic.oup.com/jid/issue/222/3>  
[Reviewed earlier]

**Journal of Medical Ethics**

August 2020 - Volume 46 - 8  
<http://jme.bmj.com/content/current>  
[Reviewed earlier]

**Journal of Patient-Centered Research and Reviews**

Volume 7, Issue 3 (2020)  
<https://digitalrepository.aurorahealthcare.org/jpcrr/>  
[Reviewed earlier]

**Journal of Pediatrics**

August 2020 Volume 223, p1-236  
<http://www.jpeds.com/current>  
[Reviewed earlier]

**Journal of Pharmaceutical Policy and Practice**

<https://joppp.biomedcentral.com/>  
[Accessed 8 Aug 2020]  
[No new digest content identified]

**Journal of Public Health Management & Practice**

July/August 2020 - Volume 26 - Issue 4  
<https://journals.lww.com/jphmp/pages/currenttoc.aspx>  
[Reviewed earlier]

**Journal of Public Health Policy**

Volume 41, Issue 3, September 2020  
<https://link.springer.com/journal/41271/41/3>  
*Original Article*

**[The importance of effective risk communication and transparency: lessons from the dengue vaccine controversy in the Philippines](#)**

Manuel M. Dayrit, Ronald U. Mendoza...

Abstract

In 2016 the Philippine Department of Health (DOH) introduced a novel dengue vaccine in a mass immunization program to reduce the substantial economic and social burden of the disease on households and the government. The vaccine manufacturer's announcement regarding new findings on the small but increased risk of severe dengue for vaccinated seronegative patients caused turmoil as various people claimed that the vaccine caused deaths

and that health authorities are corrupt. While health department staff split—some having to preserve its reputation and others to monitor over 800,000 children administered the vaccine—communication between the frontline health workers and parents suffered. As a result, public confidence in vaccines dramatically dropped and the repercussions challenge the public health system. We examine factors that contributed to the crisis and argue for strengthening risk communication strategies and increasing transparency on decision making to counter misinformation and protect public health.

### **Journal of Refugee & Global Health**

Volume 2, Issue 2 (2019)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

### **Journal of the Royal Society – Interface**

August 2020 Volume 17 Issue 169

<https://royalsocietypublishing.org/toc/rsif/current>

[New issue; No digest content identified]

### **Journal of Travel Medicine**

Volume 27, Issue 4, May 2020

<https://academic.oup.com/jtm/issue/27/4>

[Reviewed earlier]

### **Journal of Virology**

July 2020; Volume 94, Issue 14

<http://jvi.asm.org/content/current>

[Reviewed earlier]

### **The Lancet**

Aug 08, 2020 Volume 396 Number 10248 p361-446, e13-e20

<https://www.thelancet.com/journals/lancet/issue/current>

[New issue; No digest content identified]

### **The Lancet Child & Adolescent Health**

Aug 2020 Volume 4 Number 8 p555-640, e26-e34

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

### **Lancet Digital Health**

Aug 2020 Volume 2 Number 8e380-e440

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

### **Lancet Global Health**

Aug 2020 Volume 8 Number 8 e973-e1100

<http://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

### **Lancet Infectious Diseases**

Aug 2020 Volume 20 Number 8 p875-992, e180-e214

<http://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

### **Lancet Public Health**

Aug 2020 Volume 5 Number 8 e414-e459

<https://www.thelancet.com/journals/lanpub/issue/current>

*Editorial*

#### **[COVID-19: from a PHEIC to a public mental health crisis?](#)**

The Lancet Public Health

... The COVID-19 pandemic presents a public mental health challenge. As Jonathan Campion and colleagues noted in *The Lancet Psychiatry*, it will be key for countries to prevent an increase in mental issues and a reduction in mental wellbeing across populations, as well as to provide appropriate public mental health interventions. Despite the existence of effective public mental health interventions, implementation is far from adequate. Public mental health interventions will need to be proportionately targeted to groups at a high risk of mental disorder and poor mental wellbeing. The unequal impacts of COVID-19, the lockdown, and its socioeconomic consequences are putting greater pressure on groups whose mental health was already more precarious before the pandemic. The COVID-19 pandemic is a public mental health emergency that could exacerbate inequalities in mental health—unless concerted actions are urgently taken.

*Articles*

#### **[Impact of delays on effectiveness of contact tracing strategies for COVID-19: a modelling study](#)**

Mirjam E Kretzschmar, Ganna Rozhnova, Martin C J Bootsma, Michiel van Boven, Janneke H H M van de Wiggert, Marc J M Bonten

In countries with declining numbers of confirmed cases of COVID-19, lockdown measures are gradually being lifted. However, even if most physical distancing measures are continued, other public health measures will be needed to control the epidemic. Contact tracing via conventional methods or mobile app technology is central to control strategies during de-escalation of physical distancing. We aimed to identify key factors for a contact tracing strategy to be successful...

### **Lancet Respiratory Medicine**

Aug 2020 Volume 8 Number 8 p743-830, e67-e69

<http://www.thelancet.com/journals/lanres/issue/current>

*Editorial*

**[COVID-19 casts light on respiratory health inequalities](#)**

The Lancet Respiratory Medicine

**Maternal and Child Health Journal**

Volume 24, Issue 8, August 2020

<https://link.springer.com/journal/10995/24/8>

[Reviewed earlier]

**Medical Decision Making (MDM)**

Volume 40 Issue 5, July 2020

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

**The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 98, Issue 2 Pages: 223-617 June 2020

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

**Nature**

Volume 584 Issue 7819, 6 August 2020

[New issue; No digest content identified]

**Nature Biotechnology**

Volume 38 Issue 8, August 2020

<https://www.nature.com/nbt/volumes/38/issues/8>

*Editorial* | 30 July 2020

**[Weighing and communicating evidence](#)**

As preliminary research findings are shared more widely and at an increasing pace, action is needed to counter the spread of misinformation.

**Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 8 Aug 2020)

[No new digest content identified]

**Nature Genetics**

Volume 52 Issue 8, August 2020

<https://www.nature.com/ng/volumes/52/issues/8>

*Editorial* | 03 August 2020

### **[Naming human genes](#)**

Gene nomenclature can be complicated, and the official naming of genes requires rational standards to avoid confusion and to maximize clarity. The HUGO Gene Nomenclature Committee has released updated guidelines for the naming of human genes, and we encourage the community to adopt these recommendations.

*Comment* | 03 August 2020

### **[Guidelines for human gene nomenclature](#)**

Standardized gene naming is crucial for effective communication about genes, and as genomics becomes increasingly important in health care, the need for a consistent language to refer to human genes becomes ever more essential. Here, we present the current HUGO Gene Nomenclature Committee (HGNC) guidelines for naming not only protein-coding genes but also RNA genes and pseudogenes, and we outline the changes in approach and ethos that have resulted from the discoveries of the past few decades.

Elsbeth A. Bruford, Bryony Braschi[...][...](#) & Susan Tweedie

### **Nature Medicine**

Volume 26 Issue 7, July 2020

<https://www.nature.com/nm/volumes/26/issues/7>

[Reviewed earlier]

### **Nature Reviews Genetics**

Volume 21 Issue 8, August 2020

<https://www.nature.com/nrg/volumes/21/issues/8>

[Reviewed earlier]

### **Nature Reviews Immunology**

Volume 20 Issue 8, August 2020

<https://www.nature.com/nri/volumes/20/issues/8>

[Reviewed earlier]

### **Nature Reviews Drug Discovery**

Volume 19 Issue 8, August 2020

<https://www.nature.com/nrd/volumes/19/issues/8>

[Reviewed earlier]

### **New England Journal of Medicine**

August 6, 2020 Vol. 383 No. 6

<http://www.nejm.org/toc/nejm/medical-journal>

*Perspective*

**[A Half-Century of Progress in Health: The National Academy of Medicine at 50: The NAM and the Quality of Health Care — Inflecting a Field](#)**

Donald M. Berwick, M.D., and Christine K. Cassel, M.D.

In 1999 and 2001, the Institute of Medicine published two landmark documents on health care quality and serious quality problems. Two decades later, focal progress in quality improvement is undeniable, but wholesale, systemic improvement has been hard to bring to scale.

*Perspective*

**[Preventing a Parallel Pandemic — A National Strategy to Protect Clinicians' Well-Being](#)**

Victor J. Dzau, M.D., Darrell Kirch, M.D., and Thomas Nasca, M.D.

**Pediatrics**

Vol. 146, Issue 2 8 Aug 2020

<https://pediatrics.aappublications.org/>

[Reviewed earlier]

**Pharmaceutics**

Volume 12, Issue 6 (June 2020) – 114 articles

<https://www.mdpi.com/1999-4923/12/5>

[Reviewed earlier]

**Pharmacoeconomics**

Volume 38, Issue 8, August 2020

<https://link.springer.com/journal/40273/38/8>

[Reviewed earlier]

**PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 8 Aug 2020)

[No new digest content identified]

**PLoS Medicine**

<http://www.plosmedicine.org/>

(Accessed 8 Aug 2020)

[No new digest content identified]

**PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

(Accessed 8 Aug 2020)

[No new digest content identified]

**PLoS One**

<http://www.plosone.org/>

*Research Article*

**[Factors influencing vaccination coverage among children age 12–23 months in Afghanistan: Analysis of the 2015 Demographic and Health Survey](#)**

Ahmad Khalid Aalemi, Karimullah Shahpar, Mohammad Yousuf Mubarak

Research Article | published 07 Aug 2020 PLOS ONE

<https://doi.org/10.1371/journal.pone.0236955>

**[Psychometric properties of the adapted measles vaccine hesitancy scale in Sudan](#)**

Majdi M. Sabahelzain, Eve Dubé, Mohamed Moukhyer, Heidi J. Larson, Bart van den Borne, Hans Bosma

Research Article | published 06 Aug 2020 PLOS ONE

<https://doi.org/10.1371/journal.pone.0237171>

**[Informed consent approaches for clinical trial participation of infants with minor parents in sub-Saharan Africa: A systematic review](#)**

Angela De Pretto-Lazarova, Domnita Oana Brancati-Badarau, Christian Burri

Research Article | published 04 Aug 2020 PLOS ONE

<https://doi.org/10.1371/journal.pone.0237088>

*Abstract*

**Background**

Regulations are vague regarding the appropriate decision-maker and authority to consent for children of minor parents participating in clinical trials. In countries with high rates of underage mothers, such as in sub-Saharan Africa, this lack of guidance may affect the rights of potential paediatric participants already bearing increased vulnerability. It can also influence the recruitment and generalizability of the research. We provide evidence and discuss informed consent management in such cases to inform best practice.

**Materials and methods**

We searched PubMed/MEDLINE, Embase, CINAHL, and Google Scholar for articles published up to March 2019. In total, 4382 articles were screened, of which 16 met our inclusion criteria. Studies addressing informed consent in clinical trials involving children with minor parents in sub-Saharan Africa were included. We performed descriptive and qualitative framework analyses. The review was registered in PROSPERO: CRD42018074220.

**Results**

Various informed consent approaches were reported. Articles supporting individual consent by minor parents based on emancipation or “mature minor” status lacked evidence in the context of research. National laws on medical care guided consent instead. When no laws or guidance existed an interpretation of the local decision-making culture, including community engagement and collaboration with local ethics committees, defined the informed consent approach.

**Conclusions**

The review emphasises that the implementation of informed consent for children with minor parents may be variable and hampered by absent or ambiguous clinical trial regulations, as well as divergent local realities. It may further be influenced by the research area and study-specific risks. Clear guidance is required to help address these challenges proactively in clinical trial planning. We provided a set of questions to be considered in the development of an ethically acceptable informed consent approach and proposed information that should be integrated into international clinical trial guidelines.

**PLoS Pathogens**

<http://journals.plos.org/plospathogens/>

[Accessed 8 Aug 2020]

[No new digest content identified]

**PNAS - Proceedings of the National Academy of Sciences of the United States of America**

<http://www.pnas.org/content/early/>

[No new digest content identified]

**Prehospital & Disaster Medicine**

Volume 35 - Issue 4 - August 2020

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

**Preventive Medicine**

Volume 137 August 2020

<https://www.sciencedirect.com/journal/preventive-medicine/vol/137/suppl/C>

[Reviewed earlier]

**Proceedings of the Royal Society B**

12 August 2020 Volume 287 Issue 1932

<https://royalsocietypublishing.org/toc/rspb/current>

[New issue; No digest content identified]

**Public Health**

Volume 183 Pages 1-152 (June 2020)

<https://www.sciencedirect.com/journal/public-health/vol/183/suppl/C>

[Reviewed earlier]

**Public Health Ethics**

*IN PROGRESS*

Volume 13, Issue 1, April 2020

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

**Public Health Reports**

Volume 135 Issue 4, July/August 2020

<https://journals.sagepub.com/toc/phrg/135/4>

[New issue; No digest content identified]

### **Qualitative Health Research**

Volume 30 Issue 11, September 2020

<http://qhr.sagepub.com/content/current>

***Special Issue: International Health***

[Reviewed earlier]

### **Research Ethics**

Volume 16 Issue 1-2, January-April 2020

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

### **Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 8 Aug 2020]

[No new digest content identified]

### **Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

*Latest articles*

6 Aug 2020

[\*\*Malaria outbreak response in urban Santo Domingo, Dominican Republic: lessons learned for community engagement\*\*](#)

Special report | English |

6 Aug 2020

[\*\*Regional System for Vaccines \(SIREVA\), laboratory surveillance and vaccine development for Streptococcus pneumoniae: bibliometric analysis, 1993-2019\*\*](#)

Original research | Spanish |

6 Aug 2020

[\*\*Exploring social innovation in health in Central America and the Caribbean\*\*](#)

Special report | English |

### **Risk Analysis**

Volume 40, Issue 7 Pages: 1321-1506 July 2020

<https://onlinelibrary.wiley.com/toc/15396924/current>

[New issue; No digest content identified]

### **Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 8 Aug 2020]

[No new digest content identified]

## **Science**

07 August 2020 Vol 369, Issue 6504

<http://www.sciencemag.org/current.dtl>

*Research Articles*

### **Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability**

By Philip J. M. Brouwer, Tom G. Caniels, Karlijn van der Straten, Jonne L. Snitselaar, Yoann Aldon, Sandhya Bangaru, Jonathan L. Torres, Nisreen M. A. Okba, Mathieu Claireaux, Gius Kerster, Arthur E. H. Bentlage, Marlies M. van Haaren, Denise Guerra, Judith A. Burger, Edith E. Schermer, Kirsten D. Verheul, Niels van der Velde, Alex van der Kooi, Jelle van Schooten, Mariëlle J. van Breemen, Tom P. L. Bijl, Kwinten Sliepen, Aafke Aartse, Ronald Derking, Ilja Bontjer, Neeltje A. Kootstra, W. Joost Wiersinga, Gestur Vidarsson, Bart L. Haagmans, Andrew B. Ward, Godelieve J. de Bree, Rogier W. Sanders, Marit J. van Gils

Science 07 Aug 2020 : 643-650 Open Access

*Isolation of 403 monoclonal antibodies from COVID-19 patients revealed convergent gene usage and multiple target epitopes.*

*Abstract*

The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has had a large impact on global health, travel, and economy. Therefore, preventative and therapeutic measures are urgently needed. Here, we isolated monoclonal antibodies from three convalescent coronavirus disease 2019 (COVID-19) patients using a SARS-CoV-2 stabilized prefusion spike protein. These antibodies had low levels of somatic hypermutation and showed a strong enrichment in VH1-69, VH3-30-3, and VH1-24 gene usage. A subset of the antibodies was able to potently inhibit authentic SARS-CoV-2 infection at a concentration as low as 0.007 micrograms per milliliter. Competition and electron microscopy studies illustrate that the SARS-CoV-2 spike protein contains multiple distinct antigenic sites, including several receptor-binding domain (RBD) epitopes as well as non-RBD epitopes. In addition to providing guidance for vaccine design, the antibodies described here are promising candidates for COVID-19 treatment and prevention.

## **Science Translational Medicine**

05 August 2020 Vol 12, Issue 555

<https://stm.sciencemag.org/>

[New issue; No digest content identified]

## **Social Science & Medicine**

Volume 258 August 2020

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/258/suppl/C>

[Reviewed earlier]

## **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 8 Aug 2020]

[No new digest content identified]

## **Travel Medicine and Infectious Diseases**

Volume 35 May–June 2020

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/35/suppl/C>

[Reviewed earlier]

## **Tropical Medicine & International Health**

Volume 25, Issue 8 Pages: i-iv, 905-1042 August 2020

<https://onlinelibrary.wiley.com/toc/13653156/current>

[New issue; No digest content identified]

## **Vaccine**

Volume 38, Issue 35 Pages 5563-5740 (31 July 2020)

<https://www.sciencedirect.com/journal/vaccine/vol/38/issue/35>

*Discussion Full text access*

### **[Ethics of a partially effective dengue vaccine: Lessons from the Philippines](#)**

Scott B. Halstead, Leah C. Katzelnick, Philip K. Russell, Lewis Markoff, ... Antonio L. Dans

Pages 5572-5576 [halsteads@erols.com](mailto:halsteads@erols.com)

*Abstract*

Dengvaxia, a chimeric yellow fever tetravalent dengue vaccine developed by SanofiPasteur is widely licensed in dengue-endemic countries. In a large cohort study Dengvaxia was found to partially protect children who had prior dengue virus (DENV) infections but sensitized seronegative children to breakthrough DENV disease of enhanced severity. In 2019, the European Medicines Agency and the US FDA issued licenses that reconciled safety issues by restricting vaccine to individuals with prior dengue infections. Using revised Dengvaxia efficacy and safety data we sought to estimate hospitalized and severe dengue cases among the more than 800,000 9 year-old children vaccinated in the Philippines. Despite an overall vaccine efficacy of 69% during 4 years post-vaccination we project there will be more than one thousand vaccinated seronegative and seropositive children hospitalized for severe dengue. Assisting these children through a program of enhanced surveillance leading to improved care deserves widespread support. Clinical responses observed during breakthrough dengue infections in vaccinated individuals counsel prudence in design of vaccine policies.

Recommendations concerning continued use of this dengue vaccine are: (1) obtain a better definition of vaccine efficacy and safety through enhanced phase 4 surveillance, (2) obtain a valid, accessible, sensitive, specific and affordable serological test that identifies past wild-type dengue virus infection and (3) clarify safety and efficacy of Dengvaxia in flavivirus immunes. In the absence of an acceptable serological screening test these unresolved ethical issues suggest Dengvaxia be given only to those signing informed consent.

*Research article Abstract only*

**[Pneumococcal vaccination in older adults: An initial analysis of social determinants of health and vaccine uptake](#)**

Justin Gatwood, Sohul Shuvo, Kenneth C. Hohmeier, Tracy Hagemann, ... Sujith Ramachandran  
Pages 5607-5617

*Research article Abstract only*

**[Self-reported vaccination status and attitudes towards mandatory vaccinations for health care workers among medical students](#)**

Ursula Kunze, Heike Schweinzer  
Pages 5695-5699

**Vaccines — Open Access Journal**

<http://www.mdpi.com/journal/vaccines>

(Accessed 8 Aug 2020)

[No new digest content]

**Value in Health**

July 2020 Volume 23, Issue 7, p827-978

[https://www.valueinhealthjournal.com/issue/S1098-3015\(20\)X0009-X](https://www.valueinhealthjournal.com/issue/S1098-3015(20)X0009-X)

*COMPARATIVE-EFFECTIVENESS RESEARCH/HTA*

**[Comparative Distributional Impact of Routine Immunization and Supplementary Immunization Activities in Delivery of Measles Vaccine in Low- and Middle-Income Countries](#)**

Allison Portnoy, Mark Jit, Stéphane Helleringer, Stéphane Verguet  
p891–897

Published online: June 12, 2020

*Highlights*

:: Although evidence shows that inequalities in under-5 mortality in low- and middle-income countries are decreasing, large disparities still persist and highlight the need to prioritize inequality reduction and equity in decision-making at the global and national levels.

:: We studied the differential coverage impact of routine delivery versus supplementary immunization activities (ie, campaign) for the delivery of measles vaccine in defining and comparing an equity impact number across the 2 distinct vaccine delivery modes.

:: This analysis can enable better description of the real-world impact of different delivery platforms in reducing health inequalities and improving equity at the global and local levels and can further highlight the important role that measles supplementary immunization activities can play in reaching children from poorer households.

\* \* \* \*

**[Media/Policy Watch](#)**

This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. *Media Watch* is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial

base of newspapers, magazines and blog sources, and is segregated from *Journal Watch* above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

### **The Atlantic**

<http://www.theatlantic.com/magazine/>

*Accessed 8 Aug 2020*

[No new, unique, relevant content]

### **BBC**

<http://www.bbc.co.uk/>

*Accessed 8 Aug 2020*

[No new, unique, relevant content]

### **The Economist**

<http://www.economist.com/>

*Accessed 8 Aug 2020*

[No new, unique, relevant content]

### **Financial Times**

<http://www.ft.com/home/uk>

*Accessed 8 Aug 2020*

*Richard Feachem*

#### **[We must not wait idly for an elusive Covid-19 vaccine](#)**

...The writer is director of The Global Health Group at the University of California, San Francisco  
It is widely assumed that a Covid-19 vaccine will come to our rescue soon. This is unlikely to be true...

August 3, 2020

### **Forbes**

<http://www.forbes.com/>

*Accessed 8 Aug 2020*

12 hours ago

#### **[China Drug Maker's Shares Soar On COVID-19 Vaccine Pact With AstraZeneca](#)**

Shares among leading China pharmaceutical makers have soared amid the COVID-19 pandemic.

By [Russell Flannery](#) Forbes Staff

*Breaking /*

Aug 7, 2020

#### **[Gates Foundation Donates \\$150 Million To Distribute Covid-19 Vaccine To Developing Nations As They Struggle With Accelerating Pandemic](#)**

The donation comes on the heels of a debunked conspiracy theory about why Gates is pushing for the vaccination.

By [Elana Lyn Gross](#) Forbes Staff

*Breaking /*  
Aug 6, 2020

### **[Biden Supports Free Coronavirus Tests And Vaccines For Undocumented Immigrants](#)**

'It's in the interest of everyone, that everyone be taken care of,' said Biden.

By [Tommy Beer](#) Forbes Staff

*Breaking /*  
Aug 5, 2020

### **[Moderna Plans To Charge \\$32-37 Per Covid Vaccine Dose, Discussing Supply Deals With Several Countries](#)**

The vaccine maker has received about \$400 million in deposits from various countries for potential supply.

By [Siladitya Ray](#) Contributor

#### **Foreign Affairs**

<http://www.foreignaffairs.com/>

*Accessed 8 Aug 2020*

[No new, unique, relevant content]

#### **Foreign Policy**

<http://foreignpolicy.com/>

*Accessed 8 Aug 2020 |*

[No new, unique, relevant content]

#### **The Guardian**

<http://www.guardiannews.com/>

[No new, unique, relevant content]

#### **New Yorker**

<http://www.newyorker.com/>

*Accessed 8 Aug 2020*

Medical Dispatch

### **[America's Coronavirus Endurance Test](#)**

To defeat the virus, we will have to start thinking in years, not months.

By [Howard Markel](#)

August 6, 2020

#### **New York Times**

<http://www.nytimes.com/>

*Accessed 8 Aug 2020*

*Americas*

### **[Brazilian Billionaire Lemann Leads Initiative to Build COVID-19 Vaccine Factory](#)**

Brazilian billionaire Jorge Lemann's foundation and other business interests will fund the building of factory to produce the COVID-19 vaccine being developed by Oxford University and pharmaceutical company AstraZeneca PLC.

By Reuters Aug. 7

*Canada*

### **[Canada Has Placed Its First Vaccine Order, but Don't Expect a 'Silver Bullet'](#)**

Before the federal government announced an order for millions of doses of a still unproven vaccine, its top doctor sounded a note of caution.

By Ian Auste Aug. 7

*U.S.*

### **[Vaccine for COVID-19 Will Need Outside Expert Review, U.S. Regulator Says](#)**

The United States will need to have independent experts review COVID-19 vaccine candidates before approval, the country's top drug regulator said on Friday, offering reassurance that his agency would not cut corners in the race to roll out a vaccine.

By Reuters Aug. 7

*U.S.*

### **[Fauci Warns COVID-19 Vaccine May Be Only Partially Effective, Public Health Measures Still Needed](#)**

An approved coronavirus vaccine could end up being effective only 50-60% of the time, meaning public health measures will still be needed to keep the pandemic under control, Dr. Anthony Fauci, the top U.S. infectious diseases expert, said on Friday.

By Reuters Aug. 7

*Europe*

### **[Russia Offers to Supply Philippines With COVID-19 Vaccine](#)**

Russia is willing to supply a coronavirus vaccine to the Philippines, or team up with a local firm to mass produce it, its ambassador to Manila said on Friday, as infections in the Southeast Asian nation surge.

By Reuters Aug. 7

*Asia Pacific*

### **[Takeda to Make Novavax's COVID-19 Vaccine Candidate in Japan](#)**

Takeda Pharmaceutical will manufacture and sell up to 250 million doses of Novavax Inc's COVID-19 vaccine candidate in Japan every year, the two companies said on Friday.

By Reuters Aug. 7

*Europe*

### **[Brazil's Bolsonaro Orders \\$360 Million to Be Set Aside for AstraZeneca Coronavirus Vaccine](#)**

Brazilian President Jair Bolsonaro issued a decree on Thursday that will set aside 1.9 billion reais (\$356 million) in funds to purchase and eventually produce the potential COVID-19 vaccine being developed by AstraZeneca PLC and Oxford University researchers.

By Reuters Aug. 6

**Washington Post**

<https://www.washingtonpost.com/>

Accessed 8 Aug 2020

Opinions

**[FDA commissioner: No matter what, only a safe, effective vaccine will get our approval](#)**

by Stephen M. Hahn

*Stephen M. Hahn, a physician, is commissioner of the Food and Drug Administration.*

August 5, 2020

Since the outbreak of the covid-19 pandemic, developing a safe and effective vaccine has been an urgent worldwide priority: to save lives, and to bolster the public's confidence in returning to a semblance of normal life.

At the Food and Drug Administration and our parent agency, the Department of Health and Human Services, we recognize the vital importance of vaccine development. The framework in the United States to support a covid-19 vaccine is now in place. Testing is underway and manufacturing capacity is rapidly expanding. But let's be clear: The development effort must adhere to standards that will ensure any covid-19 vaccine's safety and effectiveness.

Large-scale clinical trials already have begun for several promising vaccine candidates. The data from these trials will enable the scientists at the FDA to determine which of these candidates has the greatest potential to provide protection from the virus, what the possible side effects are and how long immunity is likely to last. FDA scientists will need the information to decide whether approval of the vaccine for general use is justified. This fall, we expect to start identifying which vaccine candidates are truly viable.

At the same time, our colleagues at [Operation Warp Speed](#), which operates independently of the FDA as a partnership between HHS and the Defense Department, have been arranging for the stockpiling of vials and other equipment needed for a national immunization program.

Success will hinge, of course, on the data that emerges from clinical trials. This testing by its very nature takes time: It takes time for the human body to develop immunity, and it often takes time for side effects to emerge. While speed is essential in this global emergency, we at the FDA are committed to maintaining strict scientific principles and protection of those who volunteer as vaccine test subjects.

To prepare for the completion of tests and data submission, our agency has announced that any authorized or approved covid-19 vaccine would need to show that it prevents the disease or decreases its severity in [at least 50 percent](#) of people who are vaccinated. This is a reasonable standard given the nature and impact of the pandemic.

One key element in the FDA's testing requirements is assuring diversity among the test subjects. All phases of vaccine clinical development should include the people most affected thus far by covid-19, specifically [racial and ethnic minorities](#), elderly individuals, and people with other medical conditions. Only by gathering data on these populations can we gain a full understanding of a vaccine candidate's safety and effectiveness.

I have been asked repeatedly whether there has been any inappropriate pressure on the FDA to make decisions that are not based on good data and good science. I have repeatedly said that

all FDA decisions have been, and will continue to be, based solely on good science and data. The public can count on that commitment.

Once FDA scientists determine that a covid-19 vaccine candidate meets the appropriate regulatory standards for safety and efficacy, a pathway will be created by the government to make the vaccine available without delay. And, of course, after authorization or approval by the FDA, the safety of any vaccine will be closely monitored.

Since we at the FDA are the final arbiters of whether a particular vaccine is safe and effective, I cannot make any predictions about timing of an emergency use or final approval of a covid-19 vaccine. But I can attest that every FDA resource has been, and will continue to be, at the ready to facilitate clinical testing programs, and to review clinical data and manufacturing facilities. I can further provide assurances that any vaccine authorized for widespread use will meet the appropriate standards for quality, safety and efficacy.

\* \* \* \*

### **Think Tanks et al**

#### **Brookings**

<http://www.brookings.edu/>

*Accessed 8 Aug 2020*

[No new relevant content]

#### **Center for Global Development** [to 8 Aug 2020]

<http://www.cgdev.org/page/press-center>

*Accessed 8 Aug 2020*

[No new relevant content]

#### **Chatham House** [to 8 Aug 2020]

<https://www.chathamhouse.org/>

[No new relevant content]

#### **CSIS**

<https://www.csis.org/>

*Accessed 8 Aug 2020*

*Upcoming Event*

**[Online Event: The Scramble for Vaccines and the COVAX Facility](#)**

August 11, 2020

Report

**[Is It Possible to Avert Chaos in the Vaccine Scramble?](#)**

August 6, 2020 | By [J. Stephen Morrison](#), [Anna Carroll](#), [Katherine E. Bliss](#)

... If the dominance of vaccine nationalism persists into the next phase—as promising vaccines become available for mass use—the odds are high that the wealthy and powerful will secure access while the less wealthy and less powerful are left to wait in uncertainty. Such a chaotic and inequitable outcome will prolong suffering and insecurity, thwart economic recovery, and stoke global discontent....

**Council on Foreign Relations**

<http://www.cfr.org/>

Accessed 8 Aug 2020

[No new relevant content]

**Kaiser Family Foundation**

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

Accessed 8 Aug 2020

[No new relevant content]

\* \* \* \*  
\* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global, which is solely responsible for its content, and is an open access publication, subject to the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by-nc/3.0/>). Copyright is retained by CVEP.

*CVEP is a program of the GE2P2 Global Foundation – whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances. CVEP maintains an academic affiliation with the Division of Medical Ethics, NYU School of Medicine, and an operating affiliation with the Vaccine Education Center of Children’s Hospital of Philadelphia [CHOP].*

*Support for this service is provided by the [Bill & Melinda Gates Foundation](#); [PATH](#), and industry resource members [Janssen/J&J](#), [Pfizer](#), [Sanofi Pasteur U.S.](#), [Takeda](#), [Moderna Therapeutics](#) (list in formation).*

*Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.*

\* \* \* \*  
\* \* \* \*